Summary
ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of
ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in
combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous,
subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. The
purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase
2 dose (RP2D), as well as to evaluate preliminary efficacy.